



RECEIVED

OCT 24 2002

RESPONSE UNDER 37 CFR 1.116 TECH CENTER 1600/2900
EXPEDITED PROCEDURE
EXAMINING GROUP 1632

PATENT
Attorney Docket No. 213257

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Kovesdi et al.

Application No. 09/964,065

Art Unit: 1632

Examiner: Priebe, S.

Filed: September 26, 2001

For: COMPLEMENTARY
ADENOVIRAL VECTOR
SYSTEMS AND CELL LINES

PENDING CLAIMS AFTER OFFICE ACTION DATED AUGUST 14, 2002

44. A plasmid comprising a reading frame ORF6 of an E4 region of an adenovirus genome under the control of a heterologous inducible promoter.

48. A defective recombinant adenovirus that (a) requires, for replication, complementation *in trans* of one or more essential gene functions of an E1 region and an E4 region of an adenovirus genome, and (b) comprises an adenoviral genome wherein all or part of the E1 region and the whole of the E4 region, and optionally all or part of an E3 region, is deleted from the adenoviral genome.

49. The defective recombinant adenovirus of claim 48, wherein part of the E1 region is deleted.

50. The defective recombinant adenovirus of claim 48, wherein all of the E1 region is deleted.

51. The defective recombinant adenovirus of claim 49, wherein all or part of the E3 region is deleted.

52. The defective recombinant adenovirus of claim 50, wherein all or part of the E3 region is deleted.